Eli Lilly Reports post-marketing Data for Rituximab in Melanoma

Eli Lilly today announced post-marketing results for rituximab in patients with melanoma. The study demonstrated that rituximab achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of melanoma and support the continued development of rituximab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.